GOOD STOCK BUY HSP UP UP AND AWAY !

Quote

Anonymous

Guest
Shares in Hospira Inc. edged higher on Friday even as the broader market ended on a mixed note. The company's shares oscillated between $39.31 and $39.82 before finishing the day 0.91% higher at $39.78. A total of 947,084 shares were traded which is below the daily average volume of 1.03 million. Hospira's shares have gained 14.34% in the last one month, thus outperforming the S&P 500 which gained 6.26% in the same period. Moreover, the stock is currently trading near its 52-week high of $39.95.
 






Injectible drug specialist Hospira, Inc. (HSP) shot up +16.69% on good and surprising news about a new compound. Specifically, its Inflectra drug—a biosimilar medicine to Remicade— was recommended for approval by a crucial European authority for multiple treatments. In Europe, it is likely to be approved to treat rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Typically, a drug is only approved for one condition first and then may receive other indications over time. Given Remicade had sales of roughly $2 billion in Europe last year, this was huge news. In recent quarters, there has been such a tight focus on existing facilities and historical problems that few have looked to the future. Our point of view has been the issues will get fixed and the company will go on to create new and better compounds to continue to drive growth; it seems the market needed a reminder such a future was even possible.
 






******upped his position in Hospira in the second quarter by 135.3%. The guru purchased a total of 1,581,300 shares valued at $33.81 per share. Since his most recent increase the price per share has jumped 16.5%.
******now owns a total of 2.75 million shares of Hospira, representing 1.66% of the company’s shares outstanding and 0.42% of his total portfolio. when I say jump, you say how high
 












Anonymous said:
Injectible drug specialist Hospira, Inc. (HSP) shot up +16.69% on good and surprising news about a new compound. Specifically, its Inflectra drug—a biosimilar medicine to Remicade— was recommended for approval by a crucial European authority for multiple treatments. In Europe, it is likely to be approved to treat rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Typically, a drug is only approved for one condition first and then may receive other indications over time. Given Remicade had sales of roughly $2 billion in Europe last year, this was huge news. In recent quarters, there has been such a tight focus on existing facilities and historical problems that few have looked to the future. Our point of view has been the issues will get fixed and the company will go on to create new and better compounds to continue to drive growth; it seems the market needed a reminder such a future was even possible.
Click to expand...

In your dreams.
 












Anonymous said:
******upped his position in Hospira in the second quarter by 135.3%. The guru purchased a total of 1,581,300 shares valued at $33.81 per share. Since his most recent increase the price per share has jumped 16.5%.
******now owns a total of 2.75 million shares of Hospira, representing 1.66% of the company’s shares outstanding and 0.42% of his total portfolio. when I say jump, you say how high
Click to expand...

Wow ! beta of 0.87 and a short float of 2.8% with 3.56 days to cover. Shares are up 3.9% year-to-date and climbing. Dump @ $48 then buy next year when it settles @ $35
I just made 31% gain in 28 weeks dumped half of it and waiting for $48 to dump it all
If you listened you did well if you didn't you lost How easier can I make for you people
 






Hospira Inc. (NYSE: HSP) is the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to advance wellness by improving patient and caregiver safety while reducing health care costs. This could easily be a big pharmaceutical company target. The consensus price target is $42.40, and the stock started the day at $42.09.
 






Anonymous said:
Wow ! beta of 0.87 and a short float of 2.8% with 3.56 days to cover. Shares are up 3.9% year-to-date and climbing. Dump @ $48 then buy next year when it settles @ $35
I just made 31% gain in 28 weeks dumped half of it and waiting for $48 to dump it all
If you listened you did well if you didn't you lost How easier can I make for you people
Click to expand...

DUMP IT NOW its time for a slow steady slide to $35 I made enough time to SELL SELL SELL big things brewing in Chicago That will affect stock IT'S NOT A MERGER OR TAKEOVER
 






Top Bottom
Back
Quote